M O17
Pill imprint M O17 has been identified as Oxybutynin chloride extended release 15 mg.
Oxybutynin is used in the treatment of overactive bladder; urinary incontinence; dysuria; hyperhidrosis; prostatitis and belongs to the drug class urinary antispasmodics. There is no proven risk in humans during pregnancy.
Oxybutynin 15 mg is not subject to the Controlled Substances Act.
See also related documents.
Oxybutynin chloride extended release Images
- Imprint:
-
M O17
- Strength:
- 15 mg
- Color:
- Gray
- Size:
- 8.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Urinary antispasmodics
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- 00378-6015
| NDC Code | Manufacturer / Repackager |
|---|---|
| 54868-5743 | Physicians Total Care Inc (repackager) |
Note: Inactive ingredients may vary.
Advertisement
More Oxybutynin Chloride Extended Release resources
- Oxybutynin
- Oxybutynin (Wolters Kluwer)
- Oxybutynin Extended-Release Tablets (Wolters Kluwer)
- Oxybutynin Gel (Wolters Kluwer)
- Oxybutynin Syrup (Wolters Kluwer)
- Oxybutynin System (Wolters Kluwer)
- oxybutynin (Cerner Multum)
- oxybutynin topical (Cerner Multum)
- oxybutynin transdermal (Cerner Multum)
- oxybutynin (Micromedex) - Includes Dosage Information
- oxybutynin Transdermal (Micromedex) - Includes Dosage Information
- Oxybutynin Chloride (AHFS DI)
- Oxybutynin (FDA)
- Oxybutynin Chloride (FDA)
- Oxybutynin Oral Solution (FDA)
- Oxybutynin Syrup (FDA)
- Oxybutynin Chloride (Wolters Kluwer)
Search Again
